These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20358202)

  • 21. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis.
    Cohen G; Courvoisier N; Cohen JD; Zaltni S; Sany J; Combe B
    Clin Exp Rheumatol; 2005; 23(6):795-800. PubMed ID: 16396697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis.
    Laas K; Peltomaa R; Kautiainen H; Leirisalo-Repo M
    Clin Rheumatol; 2008 Jul; 27(7):927-32. PubMed ID: 18414967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapy of rheumatoid arthritis with etanercept].
    Lamprecht P; Nitschmann S
    Internist (Berl); 2009 May; 50(5):633-4. PubMed ID: 19350212
    [No Abstract]   [Full Text] [Related]  

  • 24. Acute interstitial nephritis associated with etanercept.
    Sugimoto T; Yasuda M; Sakaguchi M; Koyama T; Uzu T; Nishioka J; Kashiwagi A
    Rheumatol Int; 2008 Oct; 28(12):1283-4. PubMed ID: 18493765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Worsening injection site reactions with continued use of etanercept.
    Edwards KR; Mowad CM; Tyler WB
    J Drugs Dermatol; 2003 Apr; 2(2):184-7. PubMed ID: 12852371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is polymyositis or dermatomyositis in patients with rheumatoid arthritis induced or unveiled by anti-tumor necrosis factor treatment?
    Nagashima T; Minota S
    Clin Rheumatol; 2010 Jul; 29(7):819-20. PubMed ID: 20405301
    [No Abstract]   [Full Text] [Related]  

  • 27. Purulent pericarditis in a patient with rheumatoid arthritis treated with etanercept and methotrexate.
    Sweet DD; Isac G; Morrison B; Fenwick J; Dhingra V
    CJEM; 2007 Jan; 9(1):40-2. PubMed ID: 17391602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of type 1 diabetes in a patient treated with anti-TNF-alpha therapy for active rheumatoid arthritis.
    Tack CJ; Kleijwegt FS; Van Riel PL; Roep BO
    Diabetologia; 2009 Jul; 52(7):1442-4. PubMed ID: 19440690
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of etanercept on tenosynovitis and nodules in rheumatoid arthritis.
    Kaiser M-; Bozonnat M-; Jorgensen C; Daurès J-; Sany J
    Arthritis Rheum; 2002 Feb; 46(2):559-60. PubMed ID: 11840464
    [No Abstract]   [Full Text] [Related]  

  • 31. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study.
    Finckh A; Simard JF; Duryea J; Liang MH; Huang J; Daneel S; Forster A; Gabay C; Guerne PA
    Arthritis Rheum; 2006 Jan; 54(1):54-9. PubMed ID: 16385495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients.
    Bacquet-Deschryver H; Jouen F; Quillard M; Ménard JF; Goëb V; Lequerré T; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    J Clin Immunol; 2008 Sep; 28(5):445-55. PubMed ID: 18587633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
    Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis.
    Kaneko K; Nanki T; Hosoya T; Mizoguchi F; Miyasaka N
    Mod Rheumatol; 2010 Dec; 20(6):632-6. PubMed ID: 20617355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Etanercept compared to intraarticular corticosteroid injection in rheumatoid arthritis: double-blind, randomized pilot study.
    Roux CH; Breuil V; Valerio L; Amoretti N; Brocq O; Albert C; Grisot C; Allam Y; Chevalier P; Pradier C; Euller-Ziegler L
    J Rheumatol; 2011 Jun; 38(6):1009-11. PubMed ID: 21406499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case of tuberculous arthritis following the use of etanercept.
    Choi SW; Ahn JJ; Hwang YT; Koh SH; Cho SD
    Korean J Intern Med; 2009 Dec; 24(4):397-401. PubMed ID: 19949742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [TNFalpha inhibitors for the treatment of rheumatoid arthritis].
    Sany J; Kaiser MJ
    Ann Med Interne (Paris); 2002 Feb; 153(1):34-40. PubMed ID: 11994688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [TNF-alpha antagonist in rheumatoid arthritis. Joint destruction can be controlled].
    MMW Fortschr Med; 2003 Oct; 145(41):46. PubMed ID: 14655484
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-tumor necrosis factor therapies.
    Taylor PC
    Curr Opin Rheumatol; 2001 May; 13(3):164-9. PubMed ID: 11333343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritis.
    Duffy TN; Genta M; Moll S; Martin PY; Gabay C
    Clin Exp Rheumatol; 2006; 24(2 Suppl 41):S106. PubMed ID: 16859610
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.